Verona Pharma (VRP)

 

Latest News

Verona Pharma Files Shelf Registration Statement with SEC

Verona Pharma Files Shelf Registration Statement with SEC Shareholders' Circular and Notice of General Meeting LONDON, May 23, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies f...

Verona Pharma Presented Clinical Data at ATS 2018 that Further Highlights RPL554 as a First-in-Class Treatment for COPD

Verona Pharma Presented Clinical Data at ATS 2018 that Further Highlights RPL554 as a First-in-Class Treatment for COPD Achieved statistically significant and clinically meaningful additional improvement in peak lung function and faster onset-of-action in COPD patients with RPL554 when added to tiotropium LONDON, May 22, 2018 (GLOBE NEWSWIRE) -- ...

Verona Pharma plc : Miscellaneous

Verona Pharma plc: Miscellaneous LONDON, May 09, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will present data from its chronic obstructive pulmonary d...

Broker Forecast - Shore Capital issues a broker note on Verona Pharma PLC

Shore Capital today reaffirms its buy investment rating on Verona Pharma PLC (LON:VRP) and cut its price target to 160...

All News

DateHeadlineSource
23-05-18Verona Pharma Files Shelf Registration Statement with SECRNS
22-05-18Verona Pharma Presented Clinical Data at ATS 2018 that Further Highlights RPL554 as a First-in-Class Treatment for COPDRNS
09-05-18Verona Pharma plc : MiscellaneousRNS
08-05-18Broker Forecast - Shore Capital issues a broker note on Verona Pharma PLCStockMarketWire
08-05-18Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018RNS
04-05-18Verona Pharma to Present at Bio€quity Europe 2018RNS
03-05-18Verona Pharma plc : Result of AGMRNS
02-05-18Verona Pharma to Announce Operational Update and Financial Results for First Quarter Ended March 31, 2018RNS
11-04-18Verona Pharma chief medical officer Kenneth Newman to leaveStockMarketWire
11-04-18Broker Forecast - Shore Capital issues a broker note on Verona Pharma PLCStockMarketWire
11-04-18Verona Pharma Announces Departure of Chief Medical OfficerRNS
26-03-18Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPDRNS
21-03-18Broker Forecast - N+1 Singer issues a broker note on Verona Pharma PLCStockMarketWire
15-03-18Verona Pharma to Present at Upcoming Healthcare Investor ConferencesRNS
09-03-18Verona Pharma plc: 2017 Annual Report and Accounts and Notice of AGMRNS
09-03-18Verona Pharma plc : Grant of Options and RSUs and PDMR DealingsRNS
08-03-18Verona Pharma plc : 1st Quarter ResultsRNS
02-03-18Second Price Monitoring ExtnRNS
02-03-18Price Monitoring ExtensionRNS
02-03-18Verona Pharma welcomes trial results for cystic fibrosis treatmentStockMarketWire
02-03-18Verona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis PatientsRNS
27-02-18Verona Pharma plc ("Verona Pharma" or the "Company") Reports Operational Update and Financial Results for Full Year Ended December 31, 2017RNS
22-02-18Verona Pharma to Announce Operational Update and Financial Results for Full Year ended December 31, 2017RNS
13-02-18Verona Pharma expects to report treatment trial data ahead of scheduleStockMarketWire
13-02-18Verona Pharma Provides Clinical Development UpdateRNS
30-11-17Verona Pharma plc : Block listing Interim ReviewRNS
30-11-17Director Deals - Verona Pharma PLC (VRP)StockMarketWire
30-11-17Verona Pharma plc : PDMR DealingRNS
27-11-17Broker Forecast - N+1 Singer issues a broker note on Verona Pharma PLCStockMarketWire
07-11-17Verona Pharma losses deepenStockMarketWire
07-11-17Verona Pharma plc Operational Update and Financial Results for the Third Quarter Ended September 30, 2017RNS
07-11-17Verona Pharma Reports Patient Enrollment Progressing Ahead of Schedule in Ongoing Phase 2b Clinical Trial of RPL554 for COPD Maintenance TreatmentRNS
31-10-17Verona Pharma to Announce Operational Update and Financial Results for the Third Quarter Ended September 30, 2017RNS
31-10-17Verona Pharma to Present at Two Upcoming Investor ConferencesRNS
02-10-17Verona Pharma plc : Total voting rightsRNS
29-09-17Best AIM companies of 2017 Interactive Investor
27-09-17Verona Pharma Reports Positive Top-Line Data from U.S. Pharmacokinetic Trial Demonstrating Nebulized RPL554 Delivers Optimal Clinical Dose to PatientsRNS
19-09-17Verona to issue sharesStockMarketWire
19-09-17Verona Pharma plc : MiscellaneousRNS
07-09-17Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)RNS

RSS feeds

  • Editorial news feed for LSE:VRP Editorial
  • Regulatory news feed for LSE:VRP Regulatory